Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

NCT06698458 · View on ClinicalTrials.gov ↗

Study Summary

This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V5. The secondary objectives of the study are to: * Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall and progression-free survival. * Assess pain control * Assess rate of surgical resection in Cohort 1.

Interventions

  • DEVICE Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

Study Locations (15)

New York

  • Bassett Healthcare Network — Cooperstown
  • NYU Langone Health — New York
  • Lenox hill Hospital — New York
  • Montefiore Medical Center — The Bronx

Arizona

  • Banner MD Anderson Cancer Center — Gilbert
  • City of Hope — Goodyear
  • Honor Health — Scottsdale

Texas

  • Texas Oncology — Houston
  • Baylor College of Medicine — Houston
  • University Cancer and Diagnostic — Houston

California

  • Cedars-Sinai — Los Angeles

Florida

  • Advent Health Cancer Institute — Orlando

Georgia

  • Emory University — Atlanta

Quebec

  • Jewish General Hospital — Montreal

Other

  • Hadassah Ein Kerem — Jerusalem

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-06-17
Est. Completion 2026-12
Phase NA

Sponsor

Alpha Tau Medical

62 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06698458

The ClinicalTrials.gov registry entry for NCT06698458 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpha Tau Medical, which has 62 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention — of which Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06698458 reports 15 study locations spanning 8 distinct geographic areas — top geographies include New York, Arizona, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06698458 about?

NCT06698458 is a clinical study titled "Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer". This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classif...

What is the current status of trial NCT06698458?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-17. Estimated completion is 2026-12.

What conditions does trial NCT06698458 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06698458?

The interventions under investigation include: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06698458?

This trial is sponsored by Alpha Tau Medical, which has 62 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06698458 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial